TOKYO, Feb. 21, 2013 /PRNewswire/ -- (Feb. 20, 2013 US Time) Boston Scientific Corporation (NYSE: BSX) subsidiary Boston Scientific Japan K.K. has reached an agreement with Fukuda Denshi Co., Ltd. to market and sell the Boston Scientific Spinal Cord Precision Plus System and accessories throughout Japan. Fukuda Denshi's extensive sales resources, distribution network and service capabilities are expected to enable Boston Scientific to reach substantially more accounts, customers and patients in Japan. Fukuda Denshi will begin distributing Boston Scientific Neuromodulation products April 1, 2013.

Boston Scientific is a leading developer of Neuromodulation devices used to manage chronic neuropathic pain. The Boston Scientific Spinal Cord Precision Plus System is the only device on the market with 16 dedicated, independent current sources designed to precisely target patient pain and the only device to offer patients wireless charging and wireless remote control to treat their pain. The remote controller is designed for patient ease of use due to its small size.

"We are pleased to reach this agreement with Fukuda Denshi to distribute our Neuromodulation products in Japan," said Yusuke Naiki, president, Boston Scientific Japan. "Fukuda Denshi has been an established player in Japan for more than 70 years, with a proven track record and a long and successful history of delivering results. We look forward to a successful relationship."

Currently, more than 60,000 patients around the world are using The Precision Plus System.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit us at www.bostonscientific.com.

About Fukuda Denshi

Founded in 1939, Fukuda Denshi is a global leader in the research and development, manufacture and sale of medical electronics equipment. With corporate headquarters in Tokyo, the company supports direct sales and distributor networks globally.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the reach of our product offerings in Japan, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:

Kenichi Kitawaki
03-5322-3559 (office)
Corporate Marketing
Boston Scientific Corporation
Kenichi.Kitawaki@bsci.com

Steven Campanini
508-652-5740 (office)
Media Relations
Boston Scientific Corporation
media@bsci.com

Michael Campbell
508-650-8023 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com